ERT, the global leader in clinical endpoints data collection, announced Wednesday the acquisition of APDM Wearable Technologies (APDM, Inc.), a next-generation provider of wearables and digital biomarkers. The combined company will generate higher-fidelity and more powerful data to enable clinical trials to be more predictable, cost-effective, and efficient. Thereby, reinventing endpoint measurement. Current clinical trial assessments in movement disorders such as ParkinsonÕs disease (PD), Multiple Sclerosis (MS), and Ataxia are subjective and based on episodic visits. Consequently, drug development decisions in Central Nervous System (CNS) and other pathologies result in large-scale trials that are costly and highly unpredictable. APDMÕs wearable platform is designed to address these challenges by providing precision motion data collected with medical-grade wearable sensors and novel digital endpoints to guide critical decision-making and allow for more objective, efficient, and effective evaluation of therapies.